ABL’s most notable contributions have been in the research and development of therapies to treat HIV and AIDS in partnership with the National Institutes of Health (NIH) and other government agencies. As the company and its collaborations with the government matured, its leadership recognized that clinical stage GMP manufacturing services were required to further the work. There was a need for early phase clinical material and ABL decided to build internal capabilities to support Phase I and II bioprocessing. Jarlath Keating, President and Chief Executive Officer of Rockville-based ABL, said the company is now set up to primarily support the gene therapy, viral vector and oncolytic virus markets. Keating called their current strategy a natural evolution from the infectious disease research work ABL continues to perform for the U.S. government.